Potential of gene therapy for pediatric neurotransmitter diseases: lessons from Parkinson's disease.
Gene therapy methods have continued to develop rapidly, and many initial limitations that hampered clinical application have been overcome. Thus serious consideration of clinical application of gene therapy is warranted for selected disorders in which the pathogenesis is well defined. Parkinson's disease has been the most extensively studied target of gene therapy for central nervous system disorders and shares many features with pediatric neurotransmitter diseases. Neurotransmitter replacement therapy using catecholamine-synthesizing genes and delivery of neurotrophic factors such as glial cell line-derived neurotrophic factors has been successful in animal models of Parkinson's disease. Application of gene therapy for pediatric neurotransmitter diseases will require delineating the optimal set of genes to correct the consequences of the deficiencies. The optimal anatomical targets and proper timing of the gene replacement must be understood. Safety of gene therapy vehicles and the ability to regulate gene expression will be essential for eventual clinical application.
Kang
Un Jung
UJ
Department of Neurology and Neurobiology, University of Chicago, Chicago, IL 60637, USA. unkang@uchicago.edu
Nakamura
Ken
K
D017209:Apoptosis / Q000235:genetics; D002648:Child; D015316:Genetic Therapy; D006801:Humans; D009414:Nerve Growth Factors / Q000235:genetics / Q000502:physiology; D009422:Nervous System Diseases / Q000235:genetics* / Q000628:therapy*; D018377:Neurotransmitter Agents / Q000235:genetics*; D010300:Parkinson Disease / Q000235:genetics* / Q000628:therapy*
D009414:Nerve Growth Factors; D018377:Neurotransmitter Agents